Marker Therapeutics rises on pre-clinical data from cancer therapy

Marker Therapeutics

31/05/2023 14:21

(Updates)
    ** Shares of cancer immunotherapy developer Marker
Therapeutics Inc  MRKR.O  rise 30.84% to $1.74 premarket
    ** Co announces pre-clinical data from its multiple
tumor-associated antigens-specific T cell product candidate,
MT-601, in lymphoma cells
    ** Says MT-601 shows anti-tumor activity against CD19 CAR T
refractory lymphoma cells under in-vitro model
    ** Data showed that MT-601 inhibited growth of lymphoma
cells, including CD19 CAR T resistant lymphoma cells
    ** CAR-T cell therapy is a type of immunotherapy, which uses
the body's own immune system to help fight cancer and bind to a
target called CD19
    ** Co developed a in-vitro model to monitor the interaction
of T cells, a type of white blood cell, with cancerous cells
    ** Data presented provide non-clinical support for the use
of MT-601 as a treatment for patients with lymphoma and those
who have relapsed following anti-CD19 CAR T treatment - MRKR
    ** Up to last close, stock down ~50% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))